Research ＆ Development
Research ＆ Development
Innovative Science & Technologies Supporting Health and Well-being
—from Pharmaceutical to Beauty and Nutrition
Innovative Science & Technologies Supporting Health and Well-being
—from Pharmaceutical to Beauty and Nutrition
Self-medication Rsearch
Self-medication Rsearch
We are advancing research and product development to meet the evolving needs of lifestyle and health over time.
We are advancing research and product development to meet the evolving needs of lifestyle and health over time.
In the self-medication business, we are actively expanding into a wide range of fields. In addition to our core OTC pharmaceutical products—such as energy drinks, general cold medicines, hair care products—we also offer a variety of health- and beauty-related products including health foods and cosmetics.
We are also actively pursuing new initiatives in product development. In the OTC pharmaceutical segment, we are responding to the trends of direct OTC conversion and switch OTC from prescription drugs. In the food segment, we are expanding into new categories such as Foods for Specified Health Use (FOSHU) and Foods with Functional Claims (FFC) to meet the needs of consumers. In the cosmetics segment, we are aiming to advanced dermatological science and formulation technologies to development of skincare products.
Our R&D activities are driven by three key consumer-focused principles, safety and quality, efficacy and usability.
- For safety and efficacy, we pursue advanced formulation design based on robust scientific evidence, including clinical data where applicable, and the development of novel ingredients.
- In terms of quality, we leverage the latest analysis technologies and accumulated expertise to develop more reliable and efficient quality methods ensuring that consumers can use our products with confidence.
- Regarding usability, we are always adopt consumer’s perspective, developing user-friendly products by considering real-life usage scenarios and exploring innovations in new dosage forms and packaging.
We are committed to developing unique and appealing ingredients by conducting basic research from both physiological and pathological perspectives, while also acquiring the latest technologies.
Our R&D efforts focus on creating high value-added products that meet the needs of consumers. To expand our lineup in fields with growing demand and potential, we are actively pursueing open innovation and collaboration with external partners, including domestic and international companies, research institutions and universities.
In the self-medication business, we are actively expanding into a wide range of fields. In addition to our core OTC pharmaceutical products—such as energy drinks, general cold medicines, hair care products—we also offer a variety of health- and beauty-related products including health foods and cosmetics.
We are also actively pursuing new initiatives in product development. In the OTC pharmaceutical segment, we are responding to the trends of direct OTC conversion and switch OTC from prescription drugs. In the food segment, we are expanding into new categories such as Foods for Specified Health Use (FOSHU) and Foods with Functional Claims (FFC) to meet the needs of consumers. In the cosmetics segment, we are aiming to advanced dermatological science and formulation technologies to development of skincare products.
Our R&D activities are driven by three key consumer-focused principles, safety and quality, efficacy and usability.
- For safety and efficacy, we pursue advanced formulation design based on robust scientific evidence, including clinical data where applicable, and the development of novel ingredients.
- In terms of quality, we leverage the latest analysis technologies and accumulated expertise to develop more reliable and efficient quality methods ensuring that consumers can use our products with confidence.
- Regarding usability, we are always adopt consumer’s perspective, developing user-friendly products by considering real-life usage scenarios and exploring innovations in new dosage forms and packaging.
We are committed to developing unique and appealing ingredients by conducting basic research from both physiological and pathological perspectives, while also acquiring the latest technologies.
Our R&D efforts focus on creating high value-added products that meet the needs of consumers. To expand our lineup in fields with growing demand and potential, we are actively pursueing open innovation and collaboration with external partners, including domestic and international companies, research institutions and universities.
Prescription pharmaceutical Division
Prescription pharmaceutical Division
We are strategically advancing drug discovery to drive further growth.
We are strategically advancing drug discovery to drive further growth.
Taisho Pharmaceutical’s prescription pharmaceutical division has its roots in 1957 with the release of Psorion, a psoriasis treatment and our first ethical drug in dermatology. We then expanded into the ethical drugs market, based on our success with Dermarin, the skin disease medication, driven by the increased demand following the implementation of universal health insurance.
As an R&D-oriented company, we are committed to discover self-developed drugs. In 1991, we released Clarith, a macrolide antibiotic now available in 130 countries. We also launched Lusefi, a type 2 diabetes medication, and Loqoa, a transdermally absorbable anti-inflammatory analgesic, in 2014 and 2016, respectively.
In 2022, we released Nanozora 30-milligram subcutaneous injection syringe, a TNFα inhibitor introduced by Ablynx and the first next-generation VHH antibody drug in Japan. Nanozora 30-milligram Autoinjector for S.C. Injection was launched in the following year, 2023. Our research into antibodies has been intensifying.
We are committed to research and development unique new drugs by leveraging advanced technologies and enhancing collaboration with outside research institutions. Recently, we focus on drug discovery using next-generation VHH antibodies.
While trying to obtain the approval of our pipeline drugs as quickly as possible, we are strengthening our pipelines through licensing activities.
Taisho Pharmaceutical’s prescription pharmaceutical division has its roots in 1957 with the release of Psorion, a psoriasis treatment and our first ethical drug in dermatology. We then expanded into the ethical drugs market, based on our success with Dermarin, the skin disease medication, driven by the increased demand following the implementation of universal health insurance.
As an R&D-oriented company, we are committed to discover self-developed drugs. In 1991, we released Clarith, a macrolide antibiotic now available in 130 countries. We also launched Lusefi, a type 2 diabetes medication, and Loqoa, a transdermally absorbable anti-inflammatory analgesic, in 2014 and 2016, respectively.
In 2022, we released Nanozora 30-milligram subcutaneous injection syringe, a TNFα inhibitor introduced by Ablynx and the first next-generation VHH antibody drug in Japan. Nanozora 30-milligram Autoinjector for S.C. Injection was launched in the following year, 2023. Our research into antibodies has been intensifying.
We are committed to research and development unique new drugs by leveraging advanced technologies and enhancing collaboration with outside research institutions. Recently, we focus on drug discovery using next-generation VHH antibodies.
While trying to obtain the approval of our pipeline drugs as quickly as possible, we are strengthening our pipelines through licensing activities.
